NCT06769295View on ClinicalTrials.gov

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Lung Cancer, Non-Small Cell

Interventions

DRUG

AK112

non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.

Trial Locations (1)

Unknown

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER